Cell Technology, Inc. OPAXIO® Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
10/2/2012 10:27:50 AM
More...
|
Cell Technology, Inc. to Report Second Quarter Financial Results on August 1
7/31/2012 9:32:49 AM
More...
|
Cell Technology, Inc. Announces Orphan Drug Designation in the European Union for Rindopepimut, a Novel EGFRvIII Vaccine for Glioblastoma
10/31/2011 6:47:48 AM
More...
|
Cell Technology, Inc. Completes Type A Meeting With FDA's Division of Oncology Drug Products: Guidance Provided for Resubmission of Pixantrone NDA for Consideration of Accelerated Approval
6/14/2011 7:07:13 AM
More...
|